United States-based Merck has received approval from the US Food and Drug Administration (FDA) for its human papillomavirus 9-valent vaccine, Gardasil 9, to be utilised as treatment for women and men aged from 27 years to 45 years, it was reported yesterday.
The company's supplemental application has been approved to expand the use of Gardasil 9, which helps in preventing certain cancers and diseases caused by the nine HPV types covered by the vaccine.
According to the Center for Disease Control and Prevention (CDC), around 14 million Americans are affected with human papillomavirus each year, and human papillomavirus viruses are associated with several other forms of cancer affecting men and women. Gardasil 9 had already received approval for use in males and females aged between nine years and 26 years.
Innovent treats first cancer patient in Phase I clinical trial of Anti-OX40 Antibody
Mayne Pharma unveils Lexette (halobetasol propionate) foam 0.05% in the US plaque psoriasis market
US FDA posts warning letters to companies illegally selling more than 58 products
Parexel Appoints Former FDA Senior Executives to Global Regulatory Consulting Services
US Patent Issued for AXA Candidate AXA1125
Omeros Names Bumol to Board of Directors
Calliditas Therapeutics announces grant of ODD by US FDA for primary biliary cholangitis
Harmony Biosciences submits Pitolisant NDA with US FDA under priority review
Calliditas Therapeutics wins US FDA orphan drug designation for primary biliary cholangitis